Numbers 2 Flashcards
% death if MCDA twins have a discordant NT >20%
30%
UK CS rate
25%
15% EMCS
10% ELCS
VBAC - risk of rupture 1 previous CS
1:200
VBAC risk of rupture if 2 previous CS
1.7%
VBAC risk of rupture if previous uterine rupture
5%
VBAC risk of rupture if previous classical CS scar
12%
VBAC risk of rupture if preterm
<0.5%
VBAC risk of rupture with oxytocin
0.8%
VBAC risk of rupture with prostaglandins
2.4%
VBAC + induction increases risk of CS by
1.5x
VBAC success rate
72-75%
VBAC + 1 previous VD success rate
85-90%
VBAC + 2 prev CS success rate
71%
VBAC success rate if previous breech
84%
VBAC success rate if previous fetal distress
74%
VBAC success rate if previous labour dystocia
64%
VBAC success rate if previous CS for dystocia, no previous VD, BMI >30 and IOL
40%
VBAC success rate if >4kg EFW
<50%
VBAC success rate if IUD
87%
VBAC rupture rate if IUD
2.4%
VBAC and instrumental delivery
39%
VBAC and OASI
5%
VBAC and perinatal death
4:10,000
VBAC and HIE
8:10,000
VBAC and unexplained SB
10:10,000
Planned vaginal breech birth perinatal mortality
2:1000
Planned vaginal cephalic birth perinatal mortality
1:1000
CS >39/40 perinatal mortality
0.5:1000
Transient neonatal respiratory morbidity in ELCS
4-5%
Transient neonatal respiratory morbidity in ELCS <39/40
6%
Transient neonatal respiratory morbidity in ELCS at 37/40
11%
Risk of maternal death in ELCS
13:100,000
Risk of maternal death in VBAC
4:100,000
% CS at full dilatation
4-5%
% of placenta praevia at term if placenta covers os at 20/40
11%
% of placenta praevia if placenta covers os at 20/40, anterior placenta and previous CS
55%
% of hysterectomy if placenta praevia and 1 previous CS
33%
% of future placenta praevia in women with current placenta praevia and 1 previous CS
23%
% of fetal varicella syndrome if VZV infection <28/40
1%
Risk of ectopic with salpingostomy
20%
Risk of malignancy of endometrial polyp
3%
% of endometrial polyps in postmenopausal women
11.8%
% of endometrial polyps in pre-menopausal women
5.8%
% of PMB caused by endometrial polyps
2-12%
% PMB caused by endometrial hyperplasia
15%
Malignant potential of endometrial hyperplasia without atypia
2-5%
Malignant potential of endometrial hyperplasia with atpyia
23-29%
Greentop 27.5-43% in 20yrs
% risk of endometrial cancer if PMB >50yo
10%
% risk of endometrial cancer if <50yo
1%
% risk of endometrial cancer in PMB >80yo
25%
% risk of endometrial cancer in PMB and diabetes
21%
% risk of endometrial cancer in PMB if diabetes and obese
29%
Increased risk of endometrial cancer on Tamoxifen
3-6x
4x when using >5years
% LBR in cystic fibrosis
80%
% PTB in cystic fibrosis
25%
% Spiramycin reduces risk of Toxoplasmosis fetal infection
60-70%
Risk of toxo transmission <4/40
<1%
Risk of toxo transmission 13/40
10%
Risk of toxo transmission 36/40
> 60%
NICE - risk of mesh erosion in subtotal hysterectomy with sacrocolpopexy
4%
NICE - risk of mesh erosion in total hysterectomy with sacrocolpopexy
11%
NICE - risk of mesh erosion in sacrohysteropexy?
8%
Risk of cancer if endometrial hyperplasia doesn’t regress in 12/12
23%
% babies colonised with chlamydia in positive mothers
50-60%
% chlamydia colonised babes that develop pneumonitis
15%
Risk of opthalmia neonatorum in gonorrhoea
28-50%
Transmission risk of primary HSV
40-50%
Transmission risk of recurrent HSV
<3%
Transmission risk in early syphilis
up to 100%
Transmission risk in late syphilis
10%
Transmission of primary CMV
40%
Transmission of recurrent CMV
1-2%
If falls pregnant on IUS/IUD - risk of ectopic pregnancy
1:20
Expulsion rate of IUS/IUD
1:20
Risk of uterine perforation with IUS/IUD
1:1000
Risk of infection with IUS/IUD
1:100
Use of COCP in BRCA1/2 can reduce ovarian cancer risk by
60%
Mesh erosion in abdominal sacrocolpopexy
2-11%
Re-operation rate in abdominal sacrocolpopexy
16.7%
Risk of anterior prolapse in SSF
8-30%
OASI overall %
2.9%
OASI in primips
6.1%
OASI in multips
1.7%
% congenital heart disease if maternal diabetes
2%
% congenital heart disease if 1 previous child affected
2%
% congenital heart disease if 2 previous children affected
10%
% congenital heart disease if mother has congenital heart disease
5%
% congenital heart disease if father has congenital heart disease
2%
% fetal loss with cystic hygroma
80-90%
% SGR occurs in monochorionic twins in absence of TTTS
15%
% SGR occurs sin monochorionic twins in TTTS
50%
% unexplained infertility
30-40%
% male factor as cause of infertility
30%
% pregnancy rates with treated lower third transverse vaginal septum
100%
% pregnancy rates with treated middle third transverse vaginal septum
40%
% pregnancy rates with treated upper third transverse vaginal septum
20%
Parvovirus transmission <15/40
15%
Parvovirus transmission 15-20/40
25%
Parvovirus transmission towards term
70%
Risk PTB <28/40 if CL at 20-24/40 <25mm
25%
Risk PTB <32/40 if CL at 20-24/40 <20mm
42.4%
Risk PTB <36/40 if CL at 20-24/40 <20mm
62%
% babes affected by transient neonatal myaesthenia gravis
20%
% unexplained infertility with mild endometriosis
30%
Ectopic rate in ART
2-8%
LBR for frozen embryos
21%
